Proton Therapy in the Treatment of Liver Metastases
Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases
Loma Linda University
35 participants
Aug 22, 2012
INTERVENTIONAL
Conditions
Summary
Local control of hepatic metastases appears to be a major determinant of overall survival. However, many patients are not suitable for resection due to medical or surgical reasons. Therefore, there is an important role for a treatment that can provide the equivalent of tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an ablative regimen of highly focused external beam radiotherapy that targets one or more discrete extracranial lesions. Published reports using SBRT to treat liver metastases have shown actuarial local control rates ranging from 50-100% with higher doses associated with better local control. In patients with metastatic liver disease, aggressive local therapy using modern radiotherapy techniques are promising and project to have a substantial role in the treatment of metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton therapy may lead to improved clinical outcomes with less morbidity, however, there is no clinical data to confirm this assertion. We thus propose a phase I study to determine the feasibility and safety of stereotactic body proton therapy in patients with liver metastases followed by a phase II study to determine the efficacy of such treatment on local control.
Eligibility
Inclusion Criteria21
- Pathologically confirmed non-lymphoma liver metastases or
- New radiographic liver lesions consistent with metastases in patients with known pathologically confirmed non-lymphoma cancer
- -3 liver lesions measurable on CT/MRI or PET/CT performed within 6 weeks prior to study entry
- Liver metastases measuring <5cm
- Life expectancy >6 months
- Disease outside the liver is allowed
- Age ≥ 18
- ECOG Performance Scale = 0-1
- Adequate bone marrow function, defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
- Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
- Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to registration on study (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)
- Adequate kidney function (serum creatinine <2mg/dL) based on chemistry panel obtained within 4 weeks prior to registration on study
- Adequate liver function, defined as total bilirubin <5 mg/dL, serum albumin >2.0g/dL, serum levels of liver enzymes < 5 times the upper limit of normal, and INR < 1.5
- Previous liver resection or ablative therapy is permitted
- Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception
- Patient must sign study specific informed consent prior to study entry
- Pretreatment evaluations required for eligibility include:
- A complete history and general physical examination
- For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration
- INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry
Exclusion Criteria10
- Prior invasive malignancy other than liver met primary (except non-melanomatous skin cancer) unless disease free for > 3years
- Prior radiotherapy that would results in overlap of radiation fields
- Prior radiotherapy to the liver
- Severe, active co-morbidity that may impact survival
- CNS metastases
- Tense ascites requiring frequent paracentesis
- Active liver infection
- Pregnancy, nursing women, or women of child bearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- Metastases location within 2cm of GI tract
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy. Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01697371